Bifidobacterium pseudominutus and application thereof

Abstract

The invention discloses a bifidobacterium pseudocatenatum and an application of the bifidobacterium pseudocatenatum. The bifidobacterium pseudocatenatum YSBP01CCTCC (China Center For Type Culture Collection) NO: M 20232067, and the application of the bifidobacterium pseudocatenatum YSBP01CCTCC NO: M 20232067. Experiments prove that the bifidobacterium pseudocaenorhabditis can enhance the antioxidant capacity of caenorhabditis elegans, prolong the life of the caenorhabditis elegans, improve the action capacity and the reproductive capacity of the caenorhabditis elegans, reduce fat accumulation, improve the mitochondrial membrane potential and delay the aging of organisms. The weight gain of high-fat diet mice is remarkably inhibited, the serum TG level of the mice is reduced, the fasting blood-glucose concentration is remarkably reduced, and obesity and type II diabetes are effectively prevented and relieved.

Description

Technical Field

[0001] The present invention belongs to the technical field of probiotics, and more specifically, relates to Bifidobacterium pseudocatenulatum and applications thereof. Background Art

[0002] With the advancement of medical technology, human life expectancy has increased. Aging and its related chronic diseases are the biggest causes of human death, which greatly threatens the physical health of the elderly. Therefore, improving the quality of life of the elderly, increasing healthy life expectancy, and reducing the disease burden of the elderly remain a huge challenge. On the other hand, the rich material conditions have led to a high incidence of obesity in modern society, and the problems caused by this have become prominent, leading to an increase in the prevalence of metabolic diseases such as diabetes, fatty liver, and cardiovascular disease, increasing the risk of death, and threatening public health. At present, reducing excessive fat accumulation and preventing or delaying adipose tissue dysfunction have been proven to be effective interventions to prolong life and healthy life.

[0003] Since Metchnikoff proposed the famous "yogurt longevity" theory in 1907, a large number of studies have shown that probiotics can delay aging by regulating intestinal flora, increasing the abundance of beneficial bacteria, reducing the number of pathogens in the intestine, and improving the body's immune and antioxidant abilities. They can also intervene in the pathogenesis of obesity and type 2 diabetes by regulating bile acid synthesis, fat and glucose metabolism. Probiotics are specific at the genus, species and strain level, and different strains usually have very different probiotic functions and effects. Therefore, separation and screening to obtain probiotic strains with excellent performance is the key to the research and development of probiotics and related products.

[0004] Bifidobacterium pseudocatenulatum is common in people of all ages and is the dominant bifidobacterium in the intestines of the Chinese population. Several strains of this species have been shown to have probiotic functions of improving sugar and lipid metabolism, regulating the body's immunity, and improving anxiety and depression. In the application of the food industry, Bifidobacterium pseudocatenulatum secretes phytase and β-glucosidase to improve the body's utilization of bread minerals and isoflavones, showing its potential as a food fermentation agent. Although many strains of this species have probiotic functions, its research on anti-aging and antioxidant effects has not yet been reported. Summary of the invention

[0005] The purpose of the present invention is to overcome the deficiencies of the prior art and provide a Bifidobacterium pseudocatenulatum.

[0006] The second object of the present invention is to provide the use of the above-mentioned Bifidobacterium pseudocatenulatum in the preparation of antioxidant products.

[0007] The third object of the present invention is to provide the use of the above-mentioned Bifidobacterium pseudocatenulatum in the preparation of anti-aging products.

[0008] The fourth object of the present invention is to provide the use of the above-mentioned Bifidobacterium pseudocatenulatum in the preparation of products for treating obesity.

[0009] The fifth object of the present invention is to provide the use of the above-mentioned Bifidobacterium pseudocatenulatum in the preparation of hypoglycemic products.

[0010] The technical solution of the present invention is summarized as follows:

[0011] Bifidobacterium Pseudocatenulatum YSBP01CCTCC NO: M20232067.

[0012] The application of the above-mentioned Bifidobacterium pseudocatenulatum in the preparation of antioxidant products.

[0013] The application of the above-mentioned Bifidobacterium pseudocatenulatum in the preparation of anti-aging products.

[0014] The application of the above-mentioned Bifidobacterium pseudocatenulatum in the preparation of products for treating obesity.

[0015] The application of the above-mentioned Bifidobacterium pseudocatenulatum in the preparation of hypoglycemic products.

[0016] The present invention has the following beneficial effects:

[0017] Experiments have shown that the Bifidobacterium Pseudocatenulatum YSBP01CCTCCNO: M 20232067 of the present invention can enhance the antioxidant capacity of Caenorhabditis elegans, prolong the life span of nematodes, improve the mobility and reproductive capacity of nematodes, reduce fat accumulation, increase mitochondrial membrane potential, and delay body aging. It can also significantly inhibit the weight gain of mice on a high-fat diet, reduce the level of serum TG in mice, and significantly reduce fasting blood sugar concentration, effectively preventing and alleviating obesity and type 2 diabetes. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The effect of YSBP01 on the life span of C. elegans N2;

[0019] Figure 2 The changes in mobility (A) and fertility (B) after feeding C. elegans with YSBP01;

[0020] Figure 3 To investigate the effect of feeding YSBP01 on the fat content of nematodes;

[0021] Figure 4To investigate the effect of feeding YSBP01 on mitochondrial membrane potential in C. elegans;

[0022] Figure 5 The antioxidant properties of YSBP01 (A: MDA content; B: SOD activity; C: GSH content; D: CAT activity);

[0023] Figure 6 Effects of YSBP01 on body weight (A, B) and serum triglycerides (C) in mice fed a high-fat diet;

[0024] Figure 7 The effect of YSBP01 on blood glucose levels in type 2 diabetic mice (fasting). DETAILED DESCRIPTION

[0025] Bifidobacterium Pseudocatenulatum YSBP01 was deposited in the China Center for Type Culture Collection on October 30, 2023. The address of the collection center is: Wuhan University, Wuhan, China, and the collection number is CCTCC NO: M 20232067.

[0026] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0027] The reagents or formulations used in the following examples are:

[0028] NGM solid medium: 3g sodium chloride, 2.5g tryptone, 17g agar powder, 25mL potassium phosphate buffer (1mol / L), 1mL 1M CaCl2 aqueous solution; 1mL 1M MgSO4 aqueous solution; distilled water to 1000mL, autoclave at 121℃ for 20min. When the temperature drops to about 60℃, add 1mL 5mg / mL cholesterol solution (the solvent is 95% ethanol aqueous solution by volume) under sterile conditions, shake well, and pour on the plate.

[0029] LB liquid medium: 5 g yeast powder, 10 g tryptone, 10 g NaCl, add distilled water to 1000 mL, and sterilize at 121°C for 20 min.

[0030] 0.5% L-cysteine ​​hydrochloride MRS liquid culture medium: MRS broth (52.2 g / L, manufacturer: Shandong Top Bioengineering Co., Ltd.), 0.5% L-cysteine ​​hydrochloride anhydrous, add distilled water to 1 L, and sterilize at 121°C for 20 min.

[0031] 0.5% L-cysteine ​​hydrochloride MRS solid medium: Add 2% agar to 0.5% L-cysteine ​​hydrochloride MRS liquid medium.

[0032] Wild-type Caenorhabditis elegans N2 and Escherichia coli OP50 were purchased from Fujian Shangyuan Bioscience Technology Co., Ltd.

[0033] The kits for measuring malondialdehyde (MDA) content, glutathione (GSH) content and catalase (CAT) enzyme activity were purchased from Nanjing Jiancheng Biological, and the kit for measuring superoxide dismutase (SOD) enzyme activity was purchased from Beyotime Biological.

[0034] M9 buffer: weigh 6 g disodium hydrogen phosphate, 3 g potassium dihydrogen phosphate, 5 g sodium chloride, and 1 mL 1 mol / L magnesium sulfate buffer, add distilled water to make up to 1000 mL, and sterilize at 121°C for 20 min.

[0035] Lysis solution: weigh 0.1 g of sodium hydroxide and add 500 μL of sodium hypochlorite solution. After the heat dissipation is completed, add 4 mL of M9 buffer to dissolve and mix. The lysate should be prepared and used immediately.

[0036] Example 1 Isolation and identification of strains

[0037] 1. Isolation of strains

[0038] Sterile oxygen-free saline was used to dilute the fecal samples of 50-year-old male volunteers from Shaoxing, China, in a gradient dilution method to obtain a concentration gradient of 10 -1 to 10 -11 Take 10 -9 , 10 -10 , 10 -11 Three gradients of bacterial solution were applied to the plate (MRS solid medium with 0.5% L-cysteine ​​hydrochloride), and after evenly applied, the plate was inverted and placed in an anaerobic culture bag for culture. The strain growth time is about 24h to 48h. A single colony suspected of being Bifidobacterium pseudomicrocystis was selected and isolated from the colony, and transferred to a new culture medium (MRS solid medium with 0.5% L-cysteine ​​hydrochloride) by streaking to continue culture. The slightly transparent, tiny single colony that grew was picked, and a 10μL pipette tip was used to gently scratch the surface of the colony, and the bacterial solution was evenly blown in 10μL pure water, and 3μL was taken for PCR amplification.

[0039] 2. Molecular Biology Identification

[0040] (1) Take 3 μL of the bacterial solution obtained in step 1 and prepare the PCR amplification system and run the program according to the following system for PCR amplification (see Tables 1 and 2).

[0041] Table 1: PCR reaction system

[0042]

[0043] Table 2: PCR reaction program

[0044]

[0045] SEQ ID NO.1 (upstream primer): 27f (5′-AGAGTTTGATCCTGGCTCAG-3′)

[0046] SEQ ID NO.2 (downstream primer): Nucleotide sequence listed: 1492r (5′-TACGGTTACCTTGTTACGACTT-3′)

[0047] (2) Prepare 1.5% agarose gel and add 10 μL Ultra GelRed (10000×) nucleic acid dye per 100 mL.

[0048] (3) 5 μL of the above PCR reaction solution was added to each well, and DL2000 marker was used as a band size control. The band size was about 327 bp, which could be preliminarily determined to be Bifidobacterium pseudocatenulatum.

[0049] (4) The sample initially identified as Bifidobacterium pseudocatenulatum was further amplified by PCR using universal primers (SEQ ID NO.1, SEQ ID NO.2). The amplified PCR liquid was sent to Beijing Qingke Biotechnology Co., Ltd. (hereinafter referred to as Qingke Biotechnology) for sequencing. After the sequencing results were obtained, the sequences were aligned on the website https: / / blast.ncbi.nlm.nih.gov / Blast.cgi to obtain the alignment results.

[0050] (5) After comparison, the sample determined to be Bifidobacterium pseudoseudocatenulatum was expanded and cultured in MRS liquid medium containing 0.5% L-cysteine ​​hydrochloride for 48 hours, and 100 μL of the bacterial solution was aspirated for PCR amplification again. After amplification, it was sent to Qingke Biotechnology for sequencing, and the remaining bacterial solution was continued to be cultured. The 16S rDNA sequence (SEQ ID No. 3) obtained by sequencing was compared with NCBI BLAST, and the similarity with Bifidobacterium pseudoseudocatenulatum in Genebank was greater than 99%, and the strain was identified as Bifidobacterium pseudoseudocatenulatum. After secondary sequencing, if it is identified as single-peak Bifidobacterium pseudotruncatum, it is pure Bifidobacterium pseudotruncatum (named: YSBP01). Centrifuge the bacterial solution, pour off the supernatant, add cryopreservation protection solution (the volume ratio of bacterial solution to cryopreservation protection solution is 1:1) (cryoprotection solution is a 60% volume concentration of glycerol aqueous solution), and store it in a -80℃ refrigerator after aliquoting. Preserve it in China Center for Type Culture Collection.

[0051] Example 2 Tolerance Evaluation of YSBP01

[0052] Bifidobacterium Pseudocatenulatum YSBP01CCTCC NO: M20232067, abbreviated as YSBP01.

[0053] 1. Evaluation of the tolerance of YSBP01 to artificial gastric juice

[0054] (1) Test method

[0055] The frozen YSBP01 was inoculated into 0.5% L-cysteine ​​hydrochloride MRS liquid medium at 1% inoculation and cultured anaerobically in a 37°C incubator. After 24 hours of culture, the bacterial solution was transferred to fresh 0.5% cysteine ​​hydrochloride MRS liquid medium at 5% inoculation and cultured anaerobically in a 37°C incubator. After 18 hours of culture, 5 ml of bacterial solution was collected under sterile conditions and centrifuged at 8000rpm for 5 minutes to separate the bacteria. The bacterial precipitate was resuspended with physiological saline and mixed thoroughly, and the bacteria were collected by centrifugation at 8000rpm for 5 minutes. YSBP01 was resuspended with equal volumes of artificial gastric juice at pH=2 and pH=3 and mixed thoroughly, and then incubated in an anaerobic environment at 37°C. The bacterial solution was incubated for 0h, 1.5h and 3h, and the bacterial solution was diluted 10 times with physiological saline, and the appropriate dilution was selected for plating. Two dilutions were selected for each sample, and two plates were made for each dilution. The coated plate was inverted and placed in a 37°C incubator for anaerobic culture. After 1-2 days of culture, the growth status of the colonies on the plate was observed, the number of colonies was recorded, and the survival rate was calculated.

[0056]

[0057] A0 is the number of colonies after incubation for 0 hours, and An is the number of colonies after incubation for n hours.

[0058] (2) Test results

[0059] The survival of YSBP01 in artificial gastric fluid is shown in Table 3.

[0060] Table 3 Statistics of tolerance to artificial gastric juice of YSBP01

[0061]

[0062] 2. Evaluation of the tolerance of YSBP01 to artificial intestinal fluid

[0063] (1) Test method

[0064] YSBP01 was resuspended with an equal volume of artificial intestinal fluid and mixed thoroughly, and then incubated at 37°C in an anaerobic environment. The bacterial solution was incubated for 0h, 4h, and 8h, and the bacterial solution was diluted 10 times with physiological saline, and the appropriate dilution was selected for plating. Two dilutions were selected for each sample, and two plates were made for each dilution. The plate after plating was inverted in a 37°C incubator for anaerobically cultured. After 1-2 days of culture, the growth status of the colonies on the plate was observed, the number of colonies was recorded, and the survival rate was calculated.

[0065]

[0066] A0 is the number of colonies after incubation for 0 hours, and An is the number of colonies after incubation for n hours.

[0067] (2) Test results

[0068] The survival of YSBP01 in artificial intestinal fluid is shown in Table 4.

[0069] Table 4 Statistics of tolerance to artificial intestinal fluid of YSBP01

[0070]

[0071] Example 3 YSBP01 lifespan test on wild-type Caenorhabditis elegans N2 (hereinafter referred to as nematode)

[0072] 1. Activation of bacteria

[0073] Take 200 μL of YSBP01 frozen at -80°C, inoculate it into 10 mL of 0.5% L-cysteine ​​hydrochloride MRS liquid culture medium, put it into an anaerobic bag, and culture it anaerobically at 37°C for 24 to 48 hours to activate the strain.

[0074] 2. Cultivation of nematodes

[0075] Escherichia coli OP50 (OD=0.5) was spread on NGM solid culture medium as nematode food, and then the nematodes were picked and placed on the surface of NGM solid culture medium, and cultured in a 20°C biochemical incubator. During the culture period, the nematodes needed to be transferred to a fresh NGM plate coated with Escherichia coli OP50 every other day (cultured to the L4 stage).

[0076] 3. Synchronization of nematodes

[0077] Collect L4 nematodes into a centrifuge tube, add 1 mL of M9 buffer to wash away excess E. coli OP50, remove the supernatant after settling, and repeat the wash 3 times. Then add 1 mL of lysis buffer and shake thoroughly, remove the supernatant, and then centrifuge (3000r / min, 1min) with M9 buffer to wash 3 times, remove the supernatant and retain the eggs, transfer the eggs to a new NGM plate, and incubate in a 20°C biochemical incubator. After about 16 to 18 hours, they will grow into L1 larvae.

[0078] 4. Determination of nematode lifespan

[0079] YSBP01 was cultured in MRS liquid medium containing 0.5% L-cysteine ​​hydrochloride to the logarithmic phase;

[0080] Escherichia coli OP50 was cultured in LB liquid medium to the logarithmic phase;

[0081] The YSBP01 and E. coli OP50 cells were collected by centrifugation at 8000 r / min for 10 min at 4°C;

[0082] 90 L1 larvae were picked and placed on NGM plates containing YSBP01 and NGM plates containing E. coli OP50, respectively, and cultured in a 20°C biochemical incubator. Every other day, all surviving nematodes were picked and transferred to fresh NGM plates coated with the same bacterial solution as above to prevent newly hatched nematodes from affecting the experimental results. The experiment continued until all nematodes died, and the nematode lifespan curve was drawn.

[0083] 5. Test results

[0084] The results are as follows Figure 1 As shown, compared with the average lifespan (13d) and the maximum lifespan (20d) of nematodes fed with E. coli OP50, the average lifespan of YSBP01 was significantly extended by 35.4% (p<0.05), and the maximum lifespan was extended by 6 days, indicating that YSBP01 can significantly extend the lifespan of nematodes.

[0085] Example 4 Effect of YSBP01 on Nematode Motility and Fertility

[0086] 1. Test methods

[0087] (1) Exercise ability is one of the key indicators of health. Exercise status and exercise ability will gradually deteriorate and weaken with the aging of the body. YSBP01 strain was used to culture nematodes. The culture method was the same as in Example 3. Only Escherichia coli OP50 was fed as the control group. On the third day, 20 nematodes were randomly selected and placed on a fresh NGM plate. After the nematodes moved freely for 30 seconds, the frequency of body bending and swinging within 20 seconds was observed using a stereo microscope. One body bending refers to the body bending from one direction to another and then returning to the original direction.

[0088] (2) The anti-aging drugs or strains to be screened should not damage the reproductive capacity of the body as a prerequisite. Reproductive capacity is one of the most critical indicators of health. Therefore, the effect of YSBP01 on the reproductive capacity of nematodes was verified using the number of offspring as an indicator. According to the method described in Example 3, the nematodes were cultured with the strain to be tested until the L4 stage, and 2 nematodes were randomly selected and placed on an NGM plate coated with YSBP01 and an NGM plate coated with Escherichia coli OP50, respectively, with 5 parallels in each group. During the nematode egg-laying period, the egg-laying adults were transferred to a new NGM plate with the same bacterial solution as above every 1 day, and the old plates continued to be placed in a 20°C biochemical incubator until the eggs hatched, and the total number of hatched larvae on the plates was counted until the nematode eggs were completely hatched.

[0089] 2. Experimental results

[0090] Compared with the E. coli OP50 control group, the body bending and swinging frequency of nematodes in the YSBP01 group increased by 18.0% and 39.8% on the 3rd and 12th days, respectively ( Figure 2 A, p < 0.05), the total egg production increased by 12.2% ( Figure 2 B, p<0.05). This indicates that feeding YSBP01 can significantly enhance the mobility and reproductive capacity of nematodes and has good anti-aging properties.

[0091] Example 5 Effects of YSBP01 on fat content and mitochondrial membrane potential in nematodes

[0092] 1. Test methods

[0093] (1) YSBP01 was used to culture nematodes. The culture method was the same as that in Example 3. Escherichia coli OP50 was used as the control group. After continuing to culture for 3 days at the L4 stage, 20 nematodes were randomly selected to measure the nematode fat by Oil Red O staining. The nematodes were rinsed 3 times with M9 buffer, the throat was sealed with 25 mM levamisole hydrochloride, 200 μL of 4% paraformaldehyde solution was added and allowed to stand for 20 min, the solution was removed and then frozen and thawed 3 times with liquid nitrogen, and then stained with 60% isopropanol Oil Red O (60% isopropanol 10 ml + Oil Red O 0.05 g). After 5 hours, the excess dye was rinsed with M9 buffer and observed with an optical microscope.

[0094] (2) C. elegans was cultured with YSBP01 in the same manner as in Example 3. Escherichia coli OP50 was used as a control group. After culturing for 3 days at the L4 stage, 20 nematodes were randomly selected and the mitochondrial membrane potential was measured using JC-1 dye. The nematodes were incubated with the freshly prepared JC-1 dye solution in the dark for 2 hours. The dye on the surface of the nematodes was washed off with M9 buffer. Red fluorescence (emission wavelength of about 590 nm) and green fluorescence (emission wavelength of 529 nm) were observed under a fluorescence microscope, photographed and recorded, and the fluorescence photographs were quantitatively calculated using Image J software.

[0095] 2. Test results

[0096] Compared with the E. coli OP50 control group, the fat content of nematodes fed with YSBP01 was significantly reduced ( Figure 3 ). Image J software was used to analyze the red light optical density of fat, and it was found that the red light optical density of nematode fat was significantly reduced after YSBP01 intervention, decreasing by 38.6% ( Figure 3 , p<0.05). Compared with OP50, JC-1 staining showed increased red fluorescence and decreased green fluorescence ( Figure 4 ), and the red-green fluorescence ratio increased by 90.0% ( Figure 4 , p<0.05) indicated that YSBP01 significantly reduced fat deposition in nematodes, thereby affecting fat metabolism in nematodes, slowing down the decline in mitochondrial membrane potential and reducing mitochondrial oxidative damage.

[0097] Example 6 Effect of YSBP01 on the Antioxidant Capacity of Nematodes

[0098] 1. Test methods

[0099] The nematodes were cultured using the YSBP01 strain, and the culture method was the same as in Example 3. Escherichia coli OP50 was fed alone as the control group. The nematodes were collected after 3 days of continuous culture at the L4 stage, and washed 3 times with M9 buffer, and then the nematodes were allowed to settle naturally. The nematodes were placed in a homogenizer, ground on ice, and centrifuged at 4°C, 4000r / min to obtain the supernatant, which was the protein homogenate. The malondialdehyde (MDA) content, superoxide dismutase (SOD) enzyme activity, glutathione (GSH) content, and catalase (CAT) enzyme activity were measured according to the operating instructions of the kit.

[0100] 2. Test results

[0101] Compared with the control group of E. coli OP50, the MDA content in nematodes fed with YSBP01 was significantly reduced by 38.0% ( Figure 5 A, p<0.05), SOD activity was significantly increased by 58.8% ( Figure 5 B, p<0.05), GSH content increased significantly by 59.5% ( Figure 5 C, p<0.05, CAT activity increased significantly by 34.5% ( Figure 5 D, p<0.05). The above results indicate that YSBP01 can enhance the antioxidant capacity of nematodes by increasing SOD activity, CAT activity and GSH content and reducing MDA content in the body.

[0102] Example 7 Analysis of the effect of YSBP01 on obesity in mice fed a high-fat diet

[0103] 1. Test methods

[0104] (1) Analysis of the effect of YSBP01 on body weight of mice fed a high-fat diet

[0105] After 1 week of adaptive feeding, 6-week-old male C57BL / 6J mice were weighed, numbered, and randomly divided into 3 groups: blank control group (NC), model control group (HFD), and YSBP01 intervention group (YSBP01). The experimental animal grouping and treatment methods are shown in Table 5:

[0106] Table 5 Experimental animal groups

[0107]

[0108] The body weight of all mice was measured at a fixed time every week, and the high-fat diet was replaced every 48 h, and the weight of the administered and remaining feed was recorded.

[0109] (2) Analysis of YSBP01 on serum triglycerides (TG) in mice fed a high-fat diet

[0110] Blood was collected from the orbital vein of mice in each group 3-5 minutes after intraperitoneal anesthesia. The blood was kept at room temperature for 30 minutes and then centrifuged at 3000 rpm for 10 minutes at 4°C. The supernatant was divided into centrifuge tubes and stored at -80°C. The TG content in the serum was analyzed using an automatic analyzer.

[0111] 2. Test results

[0112] The mice were weighed and recorded every week during the experiment. Figure 6 A and Figure 6 As shown in B, the weight of mice in the HFD group increased significantly, and the model was successfully established. After the YSBP01 group was intervened with Bifidobacterium pseudocatenulatum YSBP01, the weight of mice on a high-fat diet decreased significantly; compared with the model control group, the weight gain of the YSBP01 group was significantly lower than that of the model control group, indicating that Bifidobacterium pseudocatenulatum YSBP01 can significantly inhibit the weight gain of mice on a high-fat diet induced by a high-fat diet. Figure 6 C shows that compared with the blank control group, the TG content in the serum of the HFD group mice was significantly increased (p<0.01). After oral administration of Bifidobacterium pseudocatenulatum YSBP01, the TG content in the YSBP01 intervention group was significantly reduced compared with the HFD group (p<0.01), which indicates that YSBP01 has a good regulatory effect on triglycerides.

[0113] Example 8 YSBP01 can reduce the blood glucose level of type 2 diabetic mice (fasting)

[0114] 1. Test methods

[0115] Six-week-old healthy male C57BL / 6J mice were acclimated to the environment for 1 week and randomly divided into 4 groups: blank control group (NC), model control group (DM), metformin control group (MET), and YSBP01 intervention group (YSBP01). The dose of bacterial suspension was 1.0×10 9 CFU / mL. The experimental animal groups and treatment methods are shown in Table 6:

[0116] Table 6 Experimental animal groups

[0117]

[0118] Except for the blank control group, after 8 weeks of high-sugar and high-fat diet intervention, 40 mg / Kg / d STZ (STZ powder dissolved in 0.1 mol / L sodium citrate buffer (pH 4.5) was intraperitoneally injected, and the NC group was administered with an equal volume of 0.1 mol / L sodium citrate buffer. The injection was continued for 5 days, and blood glucose was tested every 3 days after the injection. Mice with random blood glucose>16.7 mmol / L, polydipsia, polyuria and polyphagia were considered diabetic mice.

[0119] Before the end of the 10th week experiment, the blood glucose homeostasis of mice was evaluated by oral glucose tolerance test (OGTT). The specific operation was as follows: the mice were fasted for 16 hours, but not water deprived, and then given 30% glucose solution by gavage at a dose of 2 g / kg. Blood was collected from the tail vein before (0 min) and 15, 30, 60, 90, and 120 min after gavage, and the blood glucose value of the tail tip of the mice was measured with a Roche automatic blood glucose meter.

[0120] 2. Test results

[0121] The experimental results are as follows Figure 7 As shown in the figure. The fasting blood glucose level of mice in the DM group increased significantly, and oral administration of YSBP01 significantly reduced the fasting blood glucose level of the model mice and approached that of the NC group. Its ability to reduce the fasting blood glucose level of mice was similar to that of the MET group. This indicates that YSBP01 has the effect of improving blood glucose homeostasis and increasing oral glucose tolerance in mice fed a high-fat diet.

[0122] In summary, the YSBP01 strain provided by the present invention can prolong the lifespan of nematodes, enhance mobility and reproductive ability, reduce fat accumulation, increase the production of SOD, GSH, CAT, etc. and reduce the MDA content in the body, and significantly inhibit the weight gain of mice fed a high-fat diet, reduce the level of serum TG in mice, and significantly reduce the fasting blood glucose concentration. It has antioxidant, fat-reducing, and anti-aging effects and effectively prevents and alleviates obesity and type 2 diabetes, and is a probiotic.

[0123] The product is a health food, medicine, feed or additive, and its preparation form is liquid, jelly, stick, powder, tablet, granule or capsule.

[0124] The embodiments of the present invention are described in detail above, but the present invention is not limited to the described embodiments. For those skilled in the art, various changes, modifications, substitutions and variations of these embodiments are made without departing from the principles and spirit of the present invention, and still fall within the protection scope of the present invention.

Claims

1. Bifidobacterium Pseudocatenulatum YSBP01 CCTCC NO: M20232067.

2. Use of Bifidobacterium pseudocatenulatum according to claim 1 in the preparation of antioxidant products.

3. Use of Bifidobacterium pseudocatenulatum according to claim 1 in the preparation of anti-aging products.

4. Use of Bifidobacterium pseudocatenulatum according to claim 1 in the preparation of a product for treating obesity.

5. Use of Bifidobacterium pseudocatenulatum according to claim 1 in the preparation of hypoglycemic products.

Images